Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
about
The Increasing Relevance of Tumour Histology in Determining Oncological Outcomes in Colorectal CancerAre KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneumThe molecular background of mucinous carcinoma beyond MUC2Prognostic Significance of Mucinous Histologic Subtype on Oncologic Outcomes in Patients With Colorectal Cancer.Histochemical and immunohistochemical study of mucinous rectal carcinoma.Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancerMismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.MiR-205 and MiR-373 Are Associated with Aggressive Human Mucinous Colorectal Cancer.BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerImpact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerSuccessful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.A minor (<50%) signet-ring cell component associated with poor prognosis in colorectal cancer patients: a 26-year retrospective study in ChinaMetastatic pattern in colorectal cancer is strongly influenced by histological subtype.Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review.Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC.Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component.The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease.Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer.How many diseases are colorectal cancer?Reduced rate of copy number aberrations in mucinous colorectal carcinoma.Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastasesPrognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapyBRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.Prognostic factors in relation to racial disparity in advanced colorectal cancer survival.Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.Summary of current therapeutic options for peritoneal metastases from colorectal cancer.Mucinous carcinoma of the rectum: a distinct clinicopathological entity.Insight into mucinous colorectal carcinoma: clues from etiology.Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Radiotherapy and locally advanced rectal cancer.Hepatoduodenal lymph node metastasis mimicking Klatskin tumor in a patient with sigmoid colon mucinous cancer.DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment.Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort.Mismatch repair status and synchronous metastases in colorectal cancer: A nationwide cohort study.Rectal cancer: assessment of response to neoadjuvant chemoradiation by dynamic contrast-enhanced MRI.Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study.Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues.
P2860
Q26796255-DBEA8D7D-55B4-4218-BAB6-FBBB43366CA8Q26828992-F1A00DD1-6BAE-4C77-9FB5-2FE1BDB4174BQ28073129-CB35D900-8D3E-4509-B78F-723A17C7EBC9Q28083904-8831415C-B7EB-4D66-B138-E69E1F38ACE6Q33661161-05591668-A43E-40CD-A976-081E9C8624CCQ33786579-69241399-5C4C-45EB-A410-EEBB7A605F68Q33825288-BDDAD345-3AC3-4655-A0A8-E16805CFA33DQ33931167-B5AA1980-4B54-4E2D-B7DE-BEA877485851Q34362289-8437ABAE-D17B-49F4-B5D6-13840768A76CQ34529938-FC6DEAC4-9137-443E-BF2D-4CD645FC3EE5Q34621860-4F70F496-7D23-48DE-8973-9C3DEA02EA1AQ34628085-7002E67A-1010-432A-9865-51743FE07DAFQ35069535-5CAF6B76-E6B3-435F-84DD-5DAAF06D4C32Q35195873-F3C06024-2E3B-421C-A4D3-47305C91031AQ35611934-4438DF60-9CE0-47BA-8115-319357ECCBF8Q35678364-99D0E18A-F1CA-4B92-AF7E-E7715F0BB8BEQ35974935-C04750BA-017E-4258-9D96-4BB041EEA082Q36051900-A35A89F2-57A6-4419-971B-04C9EE1FD6C2Q36125311-DB39FBC0-C709-4B01-9E0C-63CEFE5CFDAEQ36151168-0162CD8B-CA9E-423C-A040-1B37FA2FDA89Q36238965-6205C88D-B774-4746-8BD4-569FB7863C1EQ36413276-0AA00420-8B87-4A7C-9152-974E5AC3F625Q36465989-11936515-B74E-4EDE-ABE2-D76C322968E0Q36896188-54C1EB4F-9903-4178-89E3-87BA9E4BF858Q37056074-C470CCE8-F836-4144-8922-65C269AAB0BAQ37394330-FB621C9D-A32F-46CE-8539-5D9DB734B217Q37775430-7E95514E-C3E7-4C96-9513-3D65A81358F9Q38017942-C4BB08D1-7672-42FB-9DA8-BCC39705A606Q38170278-B3F56FE0-7CBE-49A1-8105-EFBC57B600AEQ38204286-CB01E618-6AEF-4D15-961A-0C49318EDC22Q38239612-D4832B2B-B917-4A39-A91F-922BA5AAC0BFQ38604995-D1B8E81F-4945-45FE-8674-D13E51E2638DQ38615028-DF1C9C60-9A44-44DC-B7EE-C5868FB27138Q38821039-97E09CD9-A705-44ED-A918-46CC8D1B87FAQ39773210-B309FB9F-CF9F-4D96-9ECC-A82971DE2B37Q41003050-3386CB50-02F2-4686-9A9B-56C1D7CC4091Q43554577-533119F3-2C28-490E-8ACB-2DB7AAC14A2BQ44393228-75B5616E-8ED2-4771-89C7-7AC2E99BBBBCQ44713711-292D6784-D66D-4C75-9164-9E98704BEA68Q47145929-68895D6F-9BBB-4B43-A250-FD980AE5C2EE
P2860
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@en
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@nl
type
label
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@en
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@nl
prefLabel
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@en
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@nl
P2093
P2860
P921
P356
P1476
Mucinous histology predicts fo ...... irinotecan-based chemotherapy.
@en
P2093
A M Baldelli
F Graziano
F Loupakis
L Giustini
P Alessandroni
P Giordani
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604955
P407
P577
2009-03-03T00:00:00Z
P5875
P6179
1008988272